A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon β1a and their combinations
Fateh et al.,
A single-center retrospective cohort study of Covid-19 medications: Remdesivir, Favipiravir,..,
medRxiv, doi:10.1101/2021.03.05.21251351 (Preprint)
Retrospective 324 hospitalized patients in Iran reporting on the use remdesivir, favipiravir, methylprednisolone, dexamethasone, and interferon β1a and their combinations. There is no control group in this study, however authors suggest that interferon β1a, corticosteroids, and remdesivir may not have a significant effect on mortality of hospitalization time.
[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
Fateh et al., 8 Mar 2021, retrospective, Iran, preprint, 7 authors.
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21251351; this version posted March 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
A single-center retrospective cohort study of Covid-19 medications:
Remdesivir, Favipiravir, Methylprednisolone, Dexamethasone, and Interferon
β1a and their combinations
Sahand Tehrani Fateh1† , Sepand Tehrani Fateh2†, Esmaeil Salehi3, Nima Rezai4,5, Nazanin
Haririan7, Abdollah Asgari3*, Amir Salehi-Najafabadi8*
1- School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
2- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- M. Montazeri Hostpital, Isfahan University of Medical Sciences, Isfahan, Iran.
4- Research Center for Immunodeficiencies, Children’s Medical Center, Tehran
University of Medical Sciences, Tehran, Iran
5- Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA),
Universal Scientific Education and Research Network (USERN), Tehran, Iran
6- Science and Research Branch, Islamic Azad University, Tehran, Iran.
7- Department of Microbiology, School of Biology, University College of Science,
University of Tehran, Tehran, Iran.
† These authors contributed equally to this work.
* Corresponding authors
Email: asalehi@khayam.ut.ac.ir
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21251351; this version posted March 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Abstract:
Many drugs have been suggested to be used for Covid-19. A suitable and efficient choice of drug
would make the course of Covid-19 easier. we have investigated the efficacy of different
treatment regimen in reducing hospitalization period (HP) and mortality of 324 confirmed
Covid-19
patients.
Received
drugs
included
single
therapy
or
combinations
of
Methylprednisolone, Remdesivir, Favipiravir, Interferon β1a, and Dexamethasone. HP and
mortality were compared between different treatment groups to evaluate efficacy of each drug.
HP and mortality were also calculated for patients in each treatment group based on their
underlying diseases and age. we suggest that using IFN-β1a, RDV and corticosteroids might not
have a significant effect on the HP or mortality of the Covid-19 patients as it was thought before.
medRxiv preprint doi: https://doi.org/10.1101/2021.03.05.21251351; this version posted March 8, 2021. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.
Late treatment
is less effective
fateh
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit